How long should I take Pexidartinib?

Pexidartinib was approved in the United States on August 2, 2019, for the treatment of adult patients with symptomatic tenosynovial giant cell tumor (TGCT) associated with severe morbidity or functional limitations that cannot be improved by surgery. Pesidartinib is the first systemic treatment approved by the U.S. Food and Drug Administration for this indication. Approval was based on data from a pivotal Phase III study (ENLIVEN), which constituted the first placebo-controlled trial of a systemic investigational treatment for tenosynovial giant cell tumor. The recommended dose of pexidartinib is 400 mg twice daily on an empty stomach (≥1 hour before a meal or ≥2 hours after a meal).

Pesidartinib is an oral capsule preparation, available in 125mg and 200mg strengths.It is usually taken twice daily on an empty stomach (≥1 hour before a meal or ≥2 hours after a meal), and may also be taken with a low-fat meal or snack (approximately 400 calories, 11-14 grams of fat). Pesidartinib may cause side effects if taken with a high-fat meal (approximately 800-1,000 calories, 55-65 grams of fat). Do not take pexidartinib without food. Take pexidartinib at about the same time each day. Take pesidartinib exactly as directed. Do not take more or less than prescribed by your doctor. Doctors may reduce the dose of pesidartinib or permanently or temporarily stop treatment, depending on how well the drug works for the patient and the side effects they experience.

Pesidartinib is not marketed in the country. There is less information on the price and other related information of pexidartinib after it is launched overseas. For more drug information and specific prices, please consult the medical consultant.